Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 2.43
Day High 2.48
Open:2.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Correvio Pharma Corp, formerly Cardiome Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are AGGRASTAT, EXEMBOL, BRINAVESS and others. The firm earns revenue from the sale of company's commercialized products. It has Europe and Rest of the world geographic segments.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
PR Newswire - Mon Jun 24, 6:00AM CDT
PR Newswire - PRNW
Mon Jun 24, 6:00AM CDT
NASDAQ: CORV   TSX: CORV
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
- CNW Group - Mon Jun 24, 6:00AM CDT
CNW Group - CMTX
Mon Jun 24, 6:00AM CDT
NASDAQ: CORV TSX: CORV
Correvio Reports First Quarter 2019 Financial Results
PR Newswire - Wed May 8, 7:00AM CDT
PR Newswire - PRNW
Wed May 8, 7:00AM CDT
Mark H.N. Corrigan , MD Commences Role as CEO, effective March 14, 2019
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.40 +2.08% increase
on 07/22/19
Period Open:3.00
Price movement based on the high, low and last over the given period.
3.25 -24.62% decrease
on 06/24/19
-0.55 (-18.33%) decrease
since 06/21/19
3-Month 2.40 +2.08% increase
on 07/22/19
Period Open:3.62
Price movement based on the high, low and last over the given period.
3.94 -37.82% decrease
on 05/09/19
-1.17 (-32.32%) decrease
since 04/23/19
52-Week 2.40 +2.08% increase
on 07/22/19
Period Open:5.50
Price movement based on the high, low and last over the given period.
6.90 -64.49% decrease
on 08/17/18
-3.05 (-55.45%) decrease
since 07/23/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).